Are Clinically Significant Cancer Detection Rates Different in Peripheral Zone Lesions Undergoing Transrectal MR-TRUS Targeted Prostate Biopsy with Local Anesthesia and Sedoanalgesia?

被引:0
|
作者
Cetin, Serhat [1 ]
Aydin, Ugur [1 ]
Alishov, Sabuhi [1 ]
Koparal, Murat Yavuz [1 ]
Bulut, Ender Cem [1 ]
Sen, Ilker [1 ]
Sozen, Sinan [1 ]
机构
[1] Gazi Univ, Dept Urol, Fac Med, Ankara, Turkiye
来源
关键词
Prostate cancer; targeted biopsy; local; sedoanalgesia; anesthesia; ULTRASOUND-GUIDED BIOPSY; ULTRASONOGRAPHY; TOLERANCE; LIDOCAINE;
D O I
10.4274/uob.galenos.2023.2023.4.1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: We aimed to compare clinically significant prostate cancer (csPC) detection rates between patients who underwent targeted prostate biopsy under sedoanalgesia and those who underwent biopsy under local anesthesia with intrarectal local anesthetic instillation (IRLI). Materials and Methods: We analyzed targeted biopsy data from 2015 to 2021 at our center. csPC detection rates of sedoanalgesia (n=56) and IRLI (n=257) groups in targeted biopsy in peripheral zone (PZ) lesions compared after Mahalanobis distance matching within the propensity score caliper method. Four variablesage, prostate specific antigen density, index lesion prostate imaging-reporting and data system score, and the number of lesions-were selected as covariates for the matching procedure. Results: After matching, 96 patients from the IRLI group and 50 patients from the sedoanalgesia group were included in the analysis. In the IRLI group, csPC was detected in 33 (34.4%) patients, whereas in the sedoanalgesia group, it was detected in 21 (42%) patients. No statistically significant difference was found between the two groups (p=0.365). Conclusions: csPC detection rates for local and sedoanalgesia are similar in PZ lesions while performing targeted transrectal biopsy.
引用
收藏
页码:111 / 115
页数:5
相关论文
共 30 条
  • [1] A Systematic Review: Are MR Targeted Biopsies as Efficient as Standard TRUS Biopsies in the Detection of Clinically Significant Prostate Cancer?
    Moore, C.
    Robertson, N.
    Arsanious, N.
    Middleton, T.
    Taneja, S.
    Villers, A.
    Klotz, L.
    Emberton, M.
    UROLOGY, 2012, 80 (03) : S136 - S137
  • [2] Utility of MRI fusion-targeted transrectal prostate biopsy and prostate health index in detection of clinically significant prostate cancer
    Leow, J.
    Yeow, Y.
    Tan, T.
    INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 : 84 - 85
  • [3] Utility of MRI fusion-targeted transrectal prostate biopsy and prostate health index detection of clinically significant prostate cancer
    Yeow, Y.
    Leow, J.
    Tan, T. W.
    BJU INTERNATIONAL, 2019, 123 : 31 - 31
  • [4] PI-RADS 5 LESIONS WITHIN THE TRANSITION ZONE ARE ASSOCIATED WITH DECREASED DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER VERSUS PERIPHERAL ZONE LESIONS IN PATIENTS UNDERGOING MRI FUSION PROSTATE BIOPSY
    Wood, Andrew
    Khooblall, Prajit
    Benidir, Tarik
    Bullen, Jennifer
    Olivares, Ruben
    Schwen, Zeyad
    Haywood, Samuel
    Klein, Eric
    Ward, Ryan
    Purysko, Andrei
    Weigh, Christopher
    JOURNAL OF UROLOGY, 2023, 209 : E611 - E611
  • [5] Transperineal Versus Transrectal Targeted Biopsy With Use of Electromagnetically-tracked MR/US Fusion Guidance Platform for the Detection of Clinically Significant Prostate Cancer
    Winoker, Jared S.
    Wajswol, Ethan
    Falagario, Ugo
    Maritini, Alberto
    Moshier, Erin
    Voutsinas, Nicholas
    Knauer, Cynthia J.
    Sfakianos, John P.
    Lewis, Sara C.
    Taouli, Bachir A.
    Rastinehad, Ardeshir R.
    UROLOGY, 2020, 146 : 278 - 285
  • [6] PERFORMANCE OF IN-BORE MR-GUIDED TARGETED PROSTATE BIOPSY FOR DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER: A MULTICENTER STUDY
    Felker, Ely
    Lee-Felker, Stephanie
    Feller, John
    May, Stuart
    Princenthal, Robert
    Cohen, Martin
    Lu, David
    Margolis, Daniel
    Kim, Grace
    Raman, Steven
    JOURNAL OF UROLOGY, 2015, 193 (04): : E827 - E827
  • [7] Transperineal Versus Transrectal Targeted Biopsy With Use of Electromagnetically-tracked MR/US Fusion Guidance Platform for the Detection of Clinically Significant Prostate Cancer EDITORIAL COMMENT
    Bhanji, Yasin
    Gorin, Michael A.
    UROLOGY, 2020, 146 : 285 - 286
  • [8] Comparing detection rates of PSMA PET/CT target biopsy vs. mpMRI targeted biopsy in detection of clinically significant prostate cancer
    Piramide, F.
    Cisero, E.
    Amparore, D.
    Checcucci, E.
    De Cillis, S. T.
    Piana, A.
    Volpi, G.
    Sica, M.
    Verri, P.
    Burgio, M.
    Meziere, J.
    Quara, A.
    Busacca, G.
    Sterrantino, A.
    Ortenzi, M.
    Mesterca, A. G.
    Mandaletti, M.
    Bignante, G.
    Garino, D.
    Rosi, F.
    Manfredi, M.
    Di Dio, M.
    Fiori, C.
    Porpiglia, F.
    EUROPEAN UROLOGY, 2024, 85 : S1109 - S1109
  • [9] Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systems
    Hanske, Julian
    Risse, Yannic
    Roghmann, Florian
    Pucheril, Daniel
    Berg, Sebastian
    Tully, Karl H.
    von Landenberg, Nicolas
    Wald, Jan
    Noldus, Joachim
    Brock, Marko
    PROSTATE, 2022, 82 (02): : 227 - 234
  • [10] Transition from Transrectal to Transperineal MRI-Fusion Prostate Biopsy Does Not Comprise Detection Rates of Clinically Significant Prostate Cancer at a Tertiary Care Center
    Hoeh, Benedikt
    Wenzel, Mike
    Humke, Clara
    Garcia, Cristina Cano
    Siech, Carolin
    Schneider, Melissa
    Lange, Carsten
    Traumann, Miriam
    Koellermann, Jens
    Preisser, Felix
    Chun, Felix K. H.
    Mandel, Philipp
    DIAGNOSTICS, 2024, 14 (11)